Meeting
2015 ASCO Annual Meeting
Phase I study of procaspase activating compound-1 (PAC-1) in the treatment of advanced malignancies.
Authors
Oana C. Danciu
University of Illinois at Chicago, Chicago, IL
Oana C. Danciu , Martin Kelly Nicholas , Rajyasree Emmadi , Hui Xie , Paul J. Hergenrother , Theodore M. Tarasow , Arkadiusz Z. Dudek
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Cytotoxic and Other Novel Agents
Clinical Trial Registration Number
NCT02355535
Citation
J Clin Oncol 33, 2015 (suppl; abstr TPS2607)
DOI
10.1200/jco.2015.33.15_suppl.tps2607
Abstract #
TPS2607
Poster Bd #
320a
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Phase I study of procaspase activating compound -1 (PAC-1) in the treatment of advanced malignancies.
First Author: Oana Cristina Danciu
Poster
2018 ASCO Annual Meeting
Phase I study of procaspase activating compound-1 (PAC-1) for treatment of advanced malignancies.
First Author: Oana C. Danciu
Poster
2019 ASCO Annual Meeting
Phase I study of procaspase activating compound -1 (PAC-1) in combination with temozolomide (TMZ) for the treatment of recurrent malignant glioma.
First Author: Martin Kelly Nicholas
Poster
2016 ASCO Annual Meeting
A phase 1 trial of vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced stage head and neck squamous cell carcinoma.
First Author: Theodoros Nicholas Teknos